Pacific Biosciences of California, Inc. reports developments in long-read sequencing systems and genomic-analysis workflows. The company designs, develops, and manufactures sequencing solutions, including HiFi long-read sequencing technology, for research applications such as human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, rare disease research, metagenomics, and reproductive genetics.
Recurring PACB updates include quarterly financial results, Revio system adoption, chemistry and library-preparation workflows, partner integrations for bioinformatics and sample preparation, research consortia using HiFi whole genome data, and governance changes. Company releases also reflect its focus on long-read sequencing following the completed disposition of short-read sequencing assets.
PacBio (PACB) will hold a conference call on November 4, 2026, to discuss its third quarter 2026 financial results.
The call begins at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). A live webcast and replay will be accessible through PacBio’s investor website.
PacBio (PACB) announced a collaboration with TychoBio to generate RNA data for training artificial intelligence models for rare disease therapy design. TychoBio plans to use PacBio HiFi and Kinnex sequencing on more than 10,000 samples, linking the design of steric blocking antisense oligonucleotides, a type of RNA-targeting compound, to their effects on cellular RNA.
TychoBio will test candidate therapies across multiple cell types. The resulting data will train models designed to predict effectiveness, effect duration and unintended effects. TychoBio also plans to expand the approach to siRNA and other RNA-targeting compounds.
PacBio (PACB) will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 4:50 PM ET in New York.
A live webcast and a replay, available for at least 30 days, can be accessed via PacBio’s investor relations website at investor.pacificbiosciences.com.
PacBio (NASDAQ:PACB) announced that its Board of Directors has appointed Mark Van Oene as President and Chief Executive Officer, effective August 5, 2026. Van Oene, previously Chief Operating Officer since 2021, also joins the Board. He succeeds Christian Henry, who is stepping down as President and CEO after six years.
According to PacBio, Henry will remain on the Board and serve as a business advisor at least through the end of 2026 to support an orderly transition. The company highlights Van Oene’s role in operational execution, commercial strategy, product development, clinical application development, and AI-related product improvements and collaborations, aligning with PacBio’s focus on long-read sequencing, clinical markets, and AI-enabled solutions.
PacBio (NASDAQ:PACB) reported Q2 2026 revenue of $39.0 million, slightly below $39.8 million in Q2 2025, driven by consumables growth and new Revio and Vega placements amid the global commercial rollout of its SPRQ-Nx chemistry for whole genome sequencing at a $345 list price per genome.
Consumable revenue was $20.1 million (up from $18.9 million), instrument revenue $12.8 million (down from $14.2 million), and service and other revenue $6.1 million (down from $6.7 million). GAAP gross profit was $12.6 million with a 32% margin; non-GAAP gross profit was $13.9 million with a 36% margin, both below prior-year levels.
GAAP operating expenses were $57.2 million, GAAP net loss $44.7 million (non-GAAP net loss $41.9 million), and GAAP net loss per share remained $0.14. PacBio ended the quarter with $236.9 million in cash, cash equivalents, and investments and expects full-year 2026 revenue of $155–$165 million. The company also implemented restructuring actions and highlighted several key scientific publications and population-scale program milestones.
PacBio (NASDAQ:PACB) announced the upcoming SPRQ-Nx chemistry and a software update for its Vega sequencing system, raising per-run HiFi output from 60 Gb to 90 Gb and lowering the U.S. list price per run from $1,100 to $995. This combination reduces cost per gigabase by about 40% and enables more samples per run across whole-genome, targeted, and synthetic biology applications.
The software update adds two-hour and four-hour runs, new and improved DNA methylation callers (5hmC, 5mC, 6mA), and user login and audit-tracking features to support 21 CFR Part 11 compliance. DNA input requirements drop from 2 µg to as low as 500 ng, and labs can multiplex up to 96 samples per run. PacBio expects chemistry and software availability by the end of the month.
PacBio (NASDAQ: PACB) announced that its management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, at 9:00 AM ET in Boston, Massachusetts. A live webcast and a replay (available for at least 30 days) will be accessible via the company’s investor website.
PacBio (NASDAQ: PACB) will hold a quarterly conference call to discuss its second quarter 2026 financial results on Wednesday, August 5, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Investors can listen live or via replay through PacBio’s investor relations website or by using the provided toll-free and international dial-in numbers.
PacBio (NASDAQ:PACB) began worldwide shipping of its SPRQ-Nx chemistry and multi-use SMRT Cells for the Revio HiFi platform, reducing sequencing costs by about 30% versus prior SPRQ chemistry.
The new consumables target a $345 list price per genome and enable sub-$300 HiFi genomes at scale, while AI-driven DeepConsensus and updated methylation models aim to improve accuracy, yield, and epigenetic insight.
PacBio (NASDAQ:PACB) announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 2:00 PM ET in New York. A live webcast and 30-day replay will be available on the investor website.